MonTa Biosciences

📍 Kongens Lyngby, Denmark🗓 Founded 2015👥 11 employees💰 Last funded Apr 2023
Biotechnology Research🌐 montabiosciences.com
Website LinkedIn
MonTa Biosciences is a clinical stage biotech company located in the DTU science park in Kgs. Lyngby, Copenhagen. Our lead candidate MBS8 is a novel TLR7 agonist formulated in micelles, which show greater therapeutic activity and better safety profiles compared to non-formulated TLR7 agonists. We are currently running a phase I clinical study in solid tumor cancer patients at sites in Denmark, Belgium and Spain and have dosed more than 20 patients. MBS8 has the unique selling points: -MBS8 can turn “Cold” tumors into “Hot” tumors -Strong anti-tumor activity in a broad range of tumor models -Unique MoA based on Neutrophil activation and tumor cell killing -Can be administered intravenously -Show synergy with PD-1/PD-L1 checkpoint inhibitors Get in touch for more info
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2015
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Denmark
1
Frequently asked questions
Who invested in MonTa Biosciences?
MonTa Biosciences has 1 investors on record on gritt.io and 1 late-stage investors.
When did MonTa Biosciences last raise funding?
The most recent investment in MonTa Biosciences recorded on gritt.io was in April 2023.
When was MonTa Biosciences founded?
MonTa Biosciences was founded in 2015.
What industry is MonTa Biosciences in?
MonTa Biosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is MonTa Biosciences based?
MonTa Biosciences is headquartered in Kongens Lyngby, Denmark.